HLB Life Science Co. Ltd Market Cap ($104.60 Million)
Market Cap & Net Worth: HLB Life Science Co. Ltd (067630)
HLB Life Science Co. Ltd market cap. HLB Life Science Co. Ltd (KQ:067630) has a market capitalization of $104.60 Million (₩154.35 Billion) as of November 2, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #18844 globally and #886 in its home market, demonstrating a -5.99% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HLB Life Science Co. Ltd's stock price ₩3295.00 by its total outstanding shares 46842300 (46.84 Million). Also see cash efficiency ratio of HLB Life Science Co. Ltd for how efficiently the company converts equity into cash flow.
HLB Life Science Co. Ltd Market Cap History (2015–2026)
HLB Life Science Co. Ltd market cap history from 2015 to 2026. Data shows growth from $58.81 Million to $104.60 Million (2.01% CAGR). Check 067630 share price today for real-time trading data and today's change.
Index Memberships
HLB Life Science Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$208.91 Billion | 0.05% | #340 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$208.91 Billion | 0.05% | #340 of 1384 |
Weight: HLB Life Science Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
HLB Life Science Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HLB Life Science Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 067630 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
HLB Life Science Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.05x
HLB Life Science Co. Ltd's market cap is 0.05 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $58.81 Million | $27.32 Billion | -$17.04 Billion | 0.00x | N/A |
| 2016 | $77.26 Million | $42.23 Billion | -$1.25 Billion | 0.00x | N/A |
| 2017 | $112.80 Million | $106.45 Billion | $7.76 Billion | 0.00x | 0.01x |
| 2018 | $252.90 Million | $102.48 Billion | -$3.07 Billion | 0.00x | N/A |
| 2019 | $408.03 Million | $114.02 Billion | -$7.60 Billion | 0.00x | N/A |
| 2020 | $399.94 Million | $91.80 Billion | -$55.80 Billion | 0.00x | N/A |
| 2021 | $366.12 Million | $53.49 Billion | -$49.15 Billion | 0.01x | N/A |
| 2022 | $327.83 Million | $99.59 Billion | -$54.28 Billion | 0.00x | N/A |
| 2023 | $354.12 Million | $97.99 Billion | -$5.98 Billion | 0.00x | N/A |
| 2024 | $317.76 Million | $102.24 Billion | $6.14 Billion | 0.00x | 0.05x |
Competitor Companies of 067630 by Market Capitalization
Companies near HLB Life Science Co. Ltd in the global market cap rankings as of November 2, 2026. Also see how large is HLB Life Science Co. Ltd's balance sheet for a full breakdown of the balance sheet.
Key companies related to HLB Life Science Co. Ltd by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #5071 globally with a market cap of $2.65 Billion USD ( ₩3.91 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #8900 globally with a market cap of $916.61 Million USD ( ₩1.35 Trillion KRW).
- NatureCell Co.Ltd (KQ:007390): Ranked #9610 globally with a market cap of $784.13 Million USD ( ₩1.16 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #10238 globally with a market cap of $694.16 Million USD ( ₩1.02 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5071 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $2.65 Billion | ₩182700.00 |
| #8900 | ST Pharm Co.Ltd | KQ:237690 | $916.61 Million | ₩72500.00 |
| #9610 | NatureCell Co.Ltd | KQ:007390 | $784.13 Million | ₩21800.00 |
| #10238 | Oscotec Inc | KQ:039200 | $694.16 Million | ₩36450.00 |
Market Capitalization of HLB Life Science Co. Ltd (2015–2026)
Market capitalization of HLB Life Science Co. Ltd from 2015 to today. Between 2015 and today, HLB Life Science Co. Ltd's market cap moved from $58.81 Million to $ 104.60 Million, with a yearly change of 2.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩104.60 Million | -14.97% |
| 2025 | ₩123.01 Million | -61.29% |
| 2024 | ₩317.76 Million | -10.27% |
| 2023 | ₩354.12 Million | +8.02% |
| 2022 | ₩327.83 Million | -10.46% |
| 2021 | ₩366.12 Million | -8.46% |
| 2020 | ₩399.94 Million | -1.98% |
| 2019 | ₩408.03 Million | +61.34% |
| 2018 | ₩252.90 Million | +124.21% |
| 2017 | ₩112.80 Million | +45.99% |
| 2016 | ₩77.26 Million | +31.38% |
| 2015 | ₩58.81 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of HLB Life Science Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $104.60 Million USD |
| MoneyControl | $104.60 Million USD |
| MarketWatch | $104.60 Million USD |
| marketcap.company | $104.60 Million USD |
| Reuters | $104.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HLB Life Science Co. Ltd
HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendoc… Read more